EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Why do signaling proteins called interferons, which recruit the immune system to attack cancer cells, start helping the tumor grow rather than shrink when they linger too long?

September 18, 2026

Vol.52 No.34

Drugs & Targets

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

FDA has granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

September 18, 2026

Vol.52 No.34

In Brief

Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute

Weizhou Zhang, who is leading research on cancer immunotherapeutics and basic mechanisms of cancer immunology, was named co-leader of the UF Health Cancer Institute’s Immuno-Oncology and Microenvironment research program.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

YOU MAY BE INTERESTED IN

When did stage 3B lung cancer become “early stage”?

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login